Form 4 for ORGO Organogenesis Holdings Inc.
Accepted 2021-07-20 00:00:00 ET · period of report 2021-07-16 · accession 0001661181-21-000062 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-07-20 | 2021-07-16+ | ORGO | Gillheeney Gary S. | Pres, CEO, Dir | M - OptEx | $2.16 | +300.0K | 292.2K | New | +$649.1K |
| DM | 2021-07-20 | 2021-07-16+ | ORGO | Gillheeney Gary S. | Pres, CEO, Dir | S - Sale+OE | $14.35 | -300.0K | 131.9K | -69% | -$4.31M |
| DM | 2021-07-20 | 2021-07-16+ | ORGO | Gillheeney Gary S. | Pres, CEO, Dir | M - OptEx | $0.00 | -300.0K | 680.1K | -31% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2021-07-16 | M | A | 24,313 | $0.99 | 156,230 | D | — | — | |
| 2 | Common | Class A Common Stock | 2021-07-16 | M | A | 115,450 | $4.04 | 271,680 | D | — | — | |
| 3 | Common | Class A Common Stock | 2021-07-16 | S | D | 110,329 | $14.58 | 161,351 | D | — | — | (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.27 to $14.99, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. |
| 4 | Common | Class A Common Stock | 2021-07-19 | M | A | 160,237 | $0.99 | 292,154 | D | — | — | |
| 5 | Common | Class A Common Stock | 2021-07-19 | S | D | 160,237 | $14.02 | 131,917 | D | — | — | (F4) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.61 to $14.38, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. |
| 6 | Common | Class A Common Stock | 2021-07-16 | S | D | 29,434 | $15.33 | 131,917 | D | — | — | (F3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.85, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. |
| 7 | Derivative | Stock Option (Right to Buy) | 2021-07-19 | M | D | 160,237 | $0.00 | 519,860 | D | $0.99 · — to 2023-07-25 | 160,237 Class A Common Stock | (F5) 100% of the shares subject to the option are fully vested and exercisable. |
| 8 | Derivative | Stock Option (Right to Buy) | 2021-07-16 | M | D | 115,450 | $0.00 | 465,392 | D | $4.04 · — to 2030-04-22 | 115,450 Class A Common Stock | (F6) The option became and continues to become exercisable in equal annual installments over four years beginning April 1, 2020. |
| 9 | Derivative | Stock Option (Right to Buy) | 2021-07-16 | M | D | 24,313 | $0.00 | 680,097 | D | $0.99 · — to 2023-07-25 | 24,313 Class A Common Stock | (F5) 100% of the shares subject to the option are fully vested and exercisable. |